Liver cancer nicely treated by high dose vitamin D for 16 weeks (early stage, in rats) – April 2018

Vitamin D3 suppresses the early stages of chemically induced hepatocarcinogenesis in rats: a dose-response analysis

Nutrire 201843:12, https://doi.org/10.1186/s41110-018-0065-2. Published: 23 April 2018
Mariana B. Tablas, Renata L. Goto, Brunno F. R. Caetano, Sérgio A. A. dos Santos and Luis F. Barbisan

VitaminDWiki

 Download the PDF from VitaminDWiki

Average of 20,000 IU/kg of body weight of vitamin D daily (G5) for 16 weeks was enough
Image

Increased Vitamin D ==> less liver cancer
Image

Background
The aim of this study was to investigate dose-response effects of vitamin D3 (VD3) supplementation on the early stages of diethylnitrosamine (DEN) and carbon tetrachloride (CCl4)-induced hepatocarcinogenesis in rats.

Methods
The animals were randomly allocated into six experimental groups (10 rats each) treated as follows: group 1: no treatment; groups 2–6: single intraperitoneal injection of N-diethylnitrosamine; groups 2–6: intragastric CCl4; groups 3–6: intragastric VD3 at

  • 10,000,
  • 20,000,
  • 40,000, and
  • 60,000 IU/kg b.w., respectively.

Results
Serum 25-hydroxyvitamin D (25-OHD) levels in the VD3-supplemented groups were significantly higher than those in the control groups (G1 and G2, p < 0.001). Serum levels of phosphate were higher in the groups supplemented with VD3 at 10,000 and 60,000 IU/kg (G3 and G6, p < 0.005). VD3 higher doses reduced cell proliferation and the number of larger placental glutathione S-transferase (GST-P)-positive hepatocellular preneoplastic lesions. Neither the DEN/CCl4 regimen nor the VD3 supplementation altered vitamin D receptor (VDR) protein expression in the liver.

Conclusion
The results indicate that high-dose VD3 supplementation reduced the development of DEN/CCl4-induced preneoplastic lesions in the liver.

4739 visitors, last modified 21 Sep, 2019,
Printer Friendly Follow this page for updates